Molecular Partners Ag -adr (MOLN)

$4.44

-0.01

(-0.22%)

Market is closed - opens 8 PM, 22 Feb 2024

Insights on Molecular Partners Ag -adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 415.0K → 2.54M (in $), with an average increase of 83.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -15.98M → -11.43M (in $), with an average increase of 39.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 70.3% return, outperforming this stock by 99.7%

Performance

  • $4.44
    $4.44
    $4.44
    downward going graph

    0.0%

    Downside

    Day's Volatility :0.0%

    Upside

    0.0%

    downward going graph
  • $3.53
    $7.32
    $4.44
    downward going graph

    20.5%

    Downside

    52 Weeks Volatility :51.78%

    Upside

    39.34%

    downward going graph

Returns

PeriodMolecular Partners Ag -adrSector (Health Care)Index (Russel 2000)
3 Months
6.46%
11.8%
0.0%
6 Months
-22.74%
8.6%
0.0%
1 Year
-29.37%
11.4%
-6.3%
3 Years
-76.66%
26.9%
-22.0%

Highlights

Market Capitalization
152.9M
Book Value
$5.98
Earnings Per Share (EPS)
-2.07
Wall Street Target Price
11.5
Profit Margin
0.0%
Operating Margin TTM
-530.85%
Return On Assets TTM
-14.88%
Return On Equity TTM
-26.64%
Revenue TTM
8.7M
Revenue Per Share TTM
0.27
Quarterly Revenue Growth YOY
7.5%
Gross Profit TTM
138.9M
EBITDA
-58.5M
Diluted Eps TTM
-2.07
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.97
EPS Estimate Next Year
-1.85
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    9%Buy
    27%Hold
    63%Sell
Based on 11 Wall street analysts offering stock ratings for Molecular Partners Ag -adr(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
3
3
4
Sell
7
7
7

Analyst Forecast

What analysts predicted

Upside of 159.01%

Current $4.44
Target $11.50

Company Financials

FY18Y/Y Change
Revenue
10.5M
↓ 48.27%
Net Income
-37.7M
↑ 45.64%
Net Profit Margin
-357.66%
↓ 230.61%
FY19Y/Y Change
Revenue
21.0M
↑ 96.84%
Net Income
-37.5M
↓ 2.02%
Net Profit Margin
-178.03%
↑ 179.63%
FY20Y/Y Change
Revenue
10.6M
↓ 54.16%
Net Income
-71.2M
↑ 72.96%
Net Profit Margin
-671.7%
↓ 493.67%
FY21Y/Y Change
Revenue
10.2M
↓ 0.15%
Net Income
-69.8M
↑ 1.63%
Net Profit Margin
-683.65%
↓ 11.95%
FY22Y/Y Change
Revenue
189.6M
↑ 1931.68%
Net Income
117.9M
↓ 284.77%
Net Profit Margin
62.17%
↑ 745.82%
FY23Y/Y Change
Revenue
8.7M
↓ 95.41%
Net Income
-59.6M
↓ 150.6%
Net Profit Margin
-685.53%
↓ 747.7%
Q2 FY22Q/Q Change
Revenue
12.3M
↓ 93.2%
Net Income
-2.8M
↓ 101.74%
Net Profit Margin
-22.69%
↓ 111.32%
Q3 FY22Q/Q Change
Revenue
2.4M
↓ 80.11%
Net Income
-12.3M
↑ 348.31%
Net Profit Margin
-511.42%
↓ 488.73%
Q4 FY22Q/Q Change
Revenue
2.7M
↑ 15.23%
Net Income
-19.9M
↑ 66.54%
Net Profit Margin
-739.14%
↓ 227.72%
Q1 FY23Q/Q Change
Revenue
3.3M
↑ 13.26%
Net Income
-16.8M
↓ 23.02%
Net Profit Margin
-502.39%
↑ 236.75%
Q2 FY23Q/Q Change
Revenue
463.4K
↓ 86.39%
Net Income
-17.9M
↑ 4.33%
Net Profit Margin
-3.9K%
↓ 3349.9%
Q3 FY23Q/Q Change
Revenue
2.5M
↑ 512.29%
Net Income
-11.4M
↓ 28.45%
Net Profit Margin
-450.18%
↑ 3402.11%
FY17Y/Y Change
Total Assets
144.4M
↓ 21.55%
Total Liabilities
27.7M
↓ 42.67%
FY18Y/Y Change
Total Assets
157.7M
↑ 7.43%
Total Liabilities
64.5M
↑ 129.12%
FY19Y/Y Change
Total Assets
108.3M
↓ 32.37%
Total Liabilities
52.4M
↓ 19.95%
FY20Y/Y Change
Total Assets
212.7M
↑ 78.73%
Total Liabilities
91.1M
↑ 58.13%
FY21Y/Y Change
Total Assets
189.0M
↓ 7.93%
Total Liabilities
71.6M
↓ 18.61%
FY22Y/Y Change
Total Assets
262.3M
↑ 51.89%
Total Liabilities
27.1M
↓ 58.56%
Q2 FY22Q/Q Change
Total Assets
313.7M
↓ 4.02%
Total Liabilities
35.0M
↓ 29.41%
Q3 FY22Q/Q Change
Total Assets
288.4M
↓ 6.06%
Total Liabilities
30.5M
↓ 11.04%
Q4 FY22Q/Q Change
Total Assets
262.3M
↓ 6.72%
Total Liabilities
27.1M
↓ 8.87%
Q1 FY23Q/Q Change
Total Assets
267.7M
↓ 6.76%
Total Liabilities
24.5M
↓ 17.43%
Q2 FY23Q/Q Change
Total Assets
257.4M
↓ 5.74%
Total Liabilities
27.4M
↑ 9.59%
Q3 FY23Q/Q Change
Total Assets
218.1M
↓ 5.37%
Total Liabilities
21.9M
↓ 10.63%
FY18Y/Y Change
Operating Cash Flow
-43.2M
↑ 6.13%
Investing Cash Flow
9.8M
↓ 53.93%
Financing Cash Flow
398.5K
↓ 50.94%
FY19Y/Y Change
Operating Cash Flow
-1.2M
↓ 97.2%
Investing Cash Flow
-20.5M
↓ 306.35%
Financing Cash Flow
-234.4K
↓ 157.91%
FY20Y/Y Change
Operating Cash Flow
-32.9M
↑ 2337.59%
Investing Cash Flow
-24.7M
↑ 9.63%
Financing Cash Flow
128.4M
↓ 49968.72%
FY21Y/Y Change
Operating Cash Flow
-99.5M
↑ 213.81%
Investing Cash Flow
-24.3M
↑ 2.26%
Financing Cash Flow
55.4M
↓ 55.32%
FY22Y/Y Change
Operating Cash Flow
118.6M
↓ 230.36%
Investing Cash Flow
-101.1M
↑ 354.74%
Financing Cash Flow
-1.6M
↓ 103.1%
Q2 FY22Q/Q Change
Operating Cash Flow
-13.2M
↓ 107.69%
Investing Cash Flow
-16.8M
↓ 82.85%
Financing Cash Flow
-292.4K
↑ 298.57%
Q3 FY22Q/Q Change
Operating Cash Flow
-18.6M
↑ 44.35%
Investing Cash Flow
-28.1M
↑ 70.92%
Financing Cash Flow
-946.8K
↑ 230.82%
Q4 FY22Q/Q Change
Operating Cash Flow
-14.3M
↓ 21.42%
Investing Cash Flow
35.9M
↓ 230.94%
Financing Cash Flow
-298.0K
↓ 67.71%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.1M
↑ 15.97%
Investing Cash Flow
4.4M
↓ 88.76%
Financing Cash Flow
-325.2K
↓ 0.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.8M
↓ 19.72%
Investing Cash Flow
4.5M
↑ 0.0%
Financing Cash Flow
-306.0K
↓ 7.74%
Q3 FY23Q/Q Change
Operating Cash Flow
-13.2M
↓ 0.67%
Investing Cash Flow
17.8M
↑ 340.5%
Financing Cash Flow
-298.0K
↑ 8.76%

Technicals Summary

Sell

Neutral

Buy

Molecular Partners Ag -adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Molecular Partners Ag -adr
Molecular Partners Ag -adr
-3.26%
-22.74%
-29.37%
-76.66%
-76.66%
Moderna, Inc.
Moderna, Inc.
-12.75%
-21.69%
-45.66%
-45.42%
349.79%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.43%
12.14%
26.84%
105.58%
126.19%
Novo Nordisk A/s
Novo Nordisk A/s
15.13%
30.68%
70.32%
233.88%
389.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.42%
19.93%
43.82%
95.68%
129.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Molecular Partners Ag -adr
Molecular Partners Ag -adr
1.71
NA
NA
-1.97
-0.27
-0.15
NA
5.98
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.5
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.93
44.91
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.26
45.26
4.51
3.29
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.4
30.4
0.57
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Molecular Partners Ag -adr
Molecular Partners Ag -adr
Sell
$152.9M
-76.66%
1.71
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$33.7B
349.79%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.2B
126.19%
27.55
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$541.4B
389.13%
45.26
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$109.1B
129.78%
30.4
36.68%

Institutional Holdings

  • Bvf Inc

    1.35%
  • Suvretta Capital Management, LLC

    1.22%
  • TANG CAPITAL MANAGEMENT LLC

    0.30%
  • Susquehanna International Group, LLP

    0.05%

Company Information

Organization
Molecular Partners Ag -adr
Employees
175
CEO
Dr. Patrick Amstutz Ph.D.
Industry
Healthcare

FAQs